Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

153 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
HVEM has a broader expression than PD-L1 and constitutes a negative prognostic marker and potential treatment target for melanoma.
Malissen N, Macagno N, Granjeaud S, Granier C, Moutardier V, Gaudy-Marqueste C, Habel N, Mandavit M, Guillot B, Pasero C, Tartour E, Ballotti R, Grob JJ, Olive D. Malissen N, et al. Among authors: moutardier v. Oncoimmunology. 2019 Sep 25;8(12):e1665976. doi: 10.1080/2162402X.2019.1665976. eCollection 2019. Oncoimmunology. 2019. PMID: 31741766 Free PMC article.
Prognostic value of PDL1 expression in pancreatic cancer.
Birnbaum DJ, Finetti P, Lopresti A, Gilabert M, Poizat F, Turrini O, Raoul JL, Delpero JR, Moutardier V, Birnbaum D, Mamessier E, Bertucci F. Birnbaum DJ, et al. Among authors: moutardier v. Oncotarget. 2016 Nov 1;7(44):71198-71210. doi: 10.18632/oncotarget.11685. Oncotarget. 2016. PMID: 27589570 Free PMC article.
Deciphering the cellular source of tumor relapse identifies CD44 as a major therapeutic target in pancreatic adenocarcinoma.
Molejon MI, Tellechea JI, Loncle C, Gayet O, Gilabert M, Duconseil P, Lopez-Millan MB, Moutardier V, Gasmi M, Garcia S, Turrini O, Ouaissi M, Poizat F, Dusetti N, Iovanna J. Molejon MI, et al. Among authors: moutardier v. Oncotarget. 2015 Apr 10;6(10):7408-23. doi: 10.18632/oncotarget.3510. Oncotarget. 2015. PMID: 25797268 Free PMC article.
A 25-gene classifier predicts overall survival in resectable pancreatic cancer.
Birnbaum DJ, Finetti P, Lopresti A, Gilabert M, Poizat F, Raoul JL, Delpero JR, Moutardier V, Birnbaum D, Mamessier E, Bertucci F. Birnbaum DJ, et al. Among authors: moutardier v. BMC Med. 2017 Sep 20;15(1):170. doi: 10.1186/s12916-017-0936-z. BMC Med. 2017. PMID: 28927421 Free PMC article.
Delayed post-pancreatectomy hemorrhage and bleeding recurrence after percutaneous endovascular treatment: risk factors from a bi-centric study of 307 consecutive patients.
Farvacque G, Guilbaud T, Loundou AD, Scemamma U, Berdah SV, Moutardier V, Chirica M, Risse O, Girard E, Birnbaum DJ. Farvacque G, et al. Among authors: moutardier v. Langenbecks Arch Surg. 2021 Sep;406(6):1893-1902. doi: 10.1007/s00423-021-02146-4. Epub 2021 Mar 24. Langenbecks Arch Surg. 2021. PMID: 33758966
Results of non-operative therapy for delayed hemorrhage after pancreaticoduodenectomy.
Beyer L, Bonmardion R, Marciano S, Hartung O, Ramis O, Chabert L, Léone M, Emungania O, Orsoni P, Barthet M, Berdah SV, Brunet C, Moutardier V. Beyer L, et al. Among authors: moutardier v. J Gastrointest Surg. 2009 May;13(5):922-8. doi: 10.1007/s11605-009-0818-6. Epub 2009 Feb 18. J Gastrointest Surg. 2009. PMID: 19224299
Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individualized medicine efforts.
Bian B, Bigonnet M, Gayet O, Loncle C, Maignan A, Gilabert M, Moutardier V, Garcia S, Turrini O, Delpero JR, Giovannini M, Grandval P, Gasmi M, Ouaissi M, Secq V, Poizat F, Nicolle R, Blum Y, Marisa L, Rubis M, Raoul JL, Bradner JE, Qi J, Lomberk G, Urrutia R, Saul A, Dusetti N, Iovanna J. Bian B, et al. Among authors: moutardier v. EMBO Mol Med. 2017 Apr;9(4):482-497. doi: 10.15252/emmm.201606975. EMBO Mol Med. 2017. PMID: 28275007 Free PMC article.
153 results